Talk:MMDA - PsychonautWiki


Active discussions
(Redirected from MMDA)

This page has not been fully approved by the PsychonautWiki administrators.

It may contain incorrect information, particularly with respect to dosage, duration, subjective effects, toxicity and other risks. It may also not meet PW style and grammar standards.

Summary sheet: MMDA
Chemical Nomenclature
Common names MMDA, 5-MeO-MDA
Substitutive name 3-Methoxy-4,5-methylenedioxyamphetamine, 5-Methoxy-3,4-methylenedioxyamphetamine
Systematic name 1-(7-Methoxy-2H-1,3-benzodioxol-5-yl)propan-2-amine
Class Membership
Psychoactive class Entactogen / Psychedelic
Chemical class Amphetamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.

Threshold 20 - 50 mg
Light 50 - 100 mg
Common 100 - 150 mg
Strong 150 - 220 mg
Heavy 220 mg +
Total 3 - 7 hours

DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.


MMDA (3-Methoxy-4,5-methylenedioxyamphetamine; also known as 5-Methoxy-MDA) is an obscure psychoactive substituted amphetamine with entactogenic and psychedelic properties. It is a closely related structural analog of mescaline and MDA.[1]

MMDA is described by Alexander Shulgin to induce 'eyelid movies' – "completely realistic innervisions". In PiHKAL, one user has reported: "Upon closing eyes hallucinations appear to be quite real in 3D, like watching a movie. First these dreams appear in black and white, but later colors start appearing. Chartreuse and magenta first appear, then blue and finally red. First I had visions of large numbers on gaming tables, then people."[2][3][citation needed]

Shulgin noted that he had synthesized MMDA in 1962 while simultaneously Dr. Gordon A also synthesized MMDA in 1962 and named it accordingly.[4]

It is strongly advised to use harm reduction practises when choosing to use this drug.


General formula of a phenethylamine molecule

MMDA, also known as 5-methoxy-3,4-methylenedioxyamphetamine, is a synthetic molecule of the substituted amphetamine family. Molecules of the amphetamine class contain a phenethylamine core featuring a phenyl ring bound to an amino (NH2) group through an ethyl chain with an additional methyl substitution at Rα. Additionally, MMDA contains substitutions at R3 and R4 of the phenyl ring with oxygen groups that are incorporated into a methylenedioxy ring through a methylene bridge. In addition, it contains a methoxy group at R5. MMDA shares this methylenedioxy ring with other drugs like MDA and MDMA but differs with its additional methoxy substitution.

It is chemically related to its precursor compound, myristicin. It is believed that MMDA plays a role in the effects and pharmacology of myristicin.[5]



This pharmacology section is incomplete.

You can help by adding to it.

MMDA likely acts as a releasing agent and reuptake inhibitor of the key monoamine neurotransmitters serotonin, dopamine and noradrenaline.

It is also theorized to act as a 5-HT2A receptor agonist. However, how the psychedelic and hallucinogenic effects work is currently not entirely known.

Alexander Shulgin notes that MMDA is responsible for some of the effects of myristicin.[6]

Subjective effects

This subjective effects section is a stub.

As such, it is still in progress and may contain incomplete or wrong information.

You can help by expanding or correcting it.

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects

Visual effects

Cognitive effects

After effects

Experience reports

There are currently anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:

Toxicity and harm potential

Short-term health concerns

Short-term physical health risks of MMDA consumption include dehydration, insomnia, hyperthermia,[7][8] and hyponatremia.[9] Continuous activity without sufficient rest or rehydration may cause body temperature to rise to dangerous levels, and loss of fluid via excessive perspiration puts the body at further risk as the stimulatory and euphoric qualities of the drug may render the user oblivious to their energy expenditure for quite some time. Diuretics such as alcohol may exacerbate these risks further.

The exact toxic dosage is unknown. It is advised to avoid very large doses of this compound.

Long-term health concerns

The neurotoxicity of MMDA is currently not known, but it can be assumed to posess a similar or greater neurotoxicity than MDMA and more compareable to MDA. Scientific study has resulted in the general agreement that, although it is physically safe to try in a responsible context, the administration of repeated or high dosages of MMDA is most likely neurotoxic in some form.

Like other powerful serotonin releasing agents, MMDA is thought to cause down-regulation of serotonin reuptake transporters in the brain. The rate at which the brain recovers from serotonergic changes is unclear. One study demonstrated lasting serotonergic changes in some animals exposed to MDMA, which likely applies to MMDA as well.[10]

Like with MDMA, the long-term heavy use of MMDA is likely similarly or even more cardiotoxic, leading to valvulopathy through its actions on the 5-HT2B receptor.[11] In one study, 28% of long-term users (2-3 doses per week for a mean of 6 years, mean of age 24.3 years) had developed clinically evident valvular heart disease.[12]

It is strongly recommended that one use harm reduction practices when using this drug.

Tolerance and addiction potential

As with other stimulants, the chronic use of MMDA can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.

Tolerance to many of the effects of MMDA develops with prolonged and repeated use. This results in users having to administer increasingly larger doses to achieve the same effects. After that, it takes about 1 months for the tolerance to be reduced to half and 2-3 months to be back at baseline (in the absence of further consumption). MMDA presents cross-tolerance with all dopaminergic and serotonergic stimulants and entactogens, meaning that after the consumption of MMDA all of these will have a reduced effect.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

  • 25x-NBOMe & 25x-NBOH - 25x compounds are highly stimulating and physically straining. Combinations with MMDA should be strictly avoided due to the risk of excessive stimulation and heart strain. This can result in increased blood pressure, vasoconstriction, panic attacks, thought loops, seizures, and heart failure in extreme cases.
  • Alcohol - Combining alcohol with stimulants can be dangerous due to the risk of accidental over-intoxication. Stimulants mask alcohol's depressant effects, which is what most people use to assess their degree of intoxication. Once the stimulant wears off, the depressant effects will be left unopposed, which can result in blackouts and severe respiratory depression. If mixing, the user should strictly limit themselves to only drinking a certain amount of alcohol per hour.
  • DXM - Combinations with DXM should be avoided due to its inhibiting effects on serotonin and norepinephrine reuptake. There is an increased risk of panic attacks and hypertensive crisis, or serotonin syndrome with serotonin releasers (MDMA, methylone, mephedrone, etc.). Monitor blood pressure carefully and avoid strenuous physical activity.
  • MDMA - Any neurotoxic effects of MDMA are likely to be increased when other stimulants are present. There is also a risk of excessive blood pressure and heart strain (cardiotoxicity).
  • MXE - Some reports suggest combinations with MXE may dangerously increase blood pressure and increase the risk of mania and psychosis.
  • Dissociatives - Both classes carry a risk of delusions, mania and psychosis, and these risk may be multiplied when combined.
  • Stimulants - MMDA may be dangerous to combine with other stimulants like cocaine as they can increase one's heart rate and blood pressure to dangerous levels.
  • Tramadol - Tramadol is known to lower the seizure threshold[13] and combinations with stimulants may further increase this risk.
  • MAOIs - This combination may increase the amount of neurotransmitters such as dopamine to dangerous or even fatal levels. Examples include syrian rue, banisteriopsis caapi, and some antidepressants.[14]
  • Stimulants - The neurotoxic effects of MMDA may be increased when combined with other stimulants.
  • Cocaine - This combination may increase strain on the heart.

Serotonin syndrome risk

Combinations with the following substances can cause dangerously high serotonin levels. Serotonin syndrome requires immediate medical attention and can be fatal if left untreated.

There is an increased risk of serotonin syndrome when MMDA is taken with many antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Additionally, if MMDA is taken with SSRIs and SNRIs, the MMDA will be significantly less powerful or may have no distinguishable effects at all.

Legal status


This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

See also

External links


  1. PiHKAL |
  7. Drug-induced hyperthermia |;jsessionid=FC30A9B157A2BAFC81048D8595714565.f02t03
  8. Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat ( / NCBI) |
  9. Vasopressin and oxytocin secretion in response to the consumption of ecstasy in a clubbing population |
  10. Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (+/-)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") ( / NCBI) |
  11. Drug-induced Valvulopathy: An Update |
  12. Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. ( / NCBI) |
  13. Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. eISSN 1937-6995. ISSN 1556-9039. OCLC 163567183. 
  14. Gillman, P. K. (2005). "Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity". British Journal of Anaesthesia. 95 (4): 434–441. doi:10.1093/bja/aei210 . eISSN 1471-6771. ISSN 0007-0912. OCLC 01537271. PMID 16051647. 
  15. Gillman, P. K. (2005). "Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity". British Journal of Anaesthesia. 95 (4): 434–441. doi:10.1093/bja/aei210 . eISSN 1471-6771. ISSN 0007-0912. OCLC 01537271. PMID 16051647. 
Return to "MMDA" page.